ANNEE 2017

Publié le 06/03/2018 à 10h55


Abadie D, Essilini A, Montastruc F, Fulda V, Gouraud A, Yéléhé-Okouma M, Jean-Pastor M, Montastruc JL. Drug-induced panic attacks : analysis of cases registered in the French pharmacovigilance database. J Psychiatr Res. 2017 ;90:60-66.

Allain N, Leven C, Falissard B, Allain JS, Batail JM, Polard E, Montastruc F, Drapier D, Naudet F. Manic switches induced by antidepressants : an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatr Scand. 2017 ;135:106-116.

Bondon-Guitton E, Mourgues T, Rousseau V, Cousty S, Cottin J, Drablier G, Micallef J, Montastruc JL. Gingival bleeding, a possible "serious" adverse drug reaction : An observational study in the French PharmacoVigilance Database. J Clin Periodontol. 2017 ;44:898-904.

Bounes V, Charriton-Dadone B, Levraut J, Delangue C, Carpentier F, Mary-Chalon S, Houze-Cerfon V, Sommet A, Houze-Cerfon CH, Ganetsky M. Predicting morphine related side effects in the ED : An international cohort study. Am J Emerg Med. 2017 ;35:531-535.

Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and Digestive Bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists : the differences do not stop there ! A pharmacovigilance study. Pharmacol Res. 2017 ;118:119-120.

Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, Bagheri H, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries : Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic. Drug Saf. 2017 ;40:809-821.

Casaurancq MC, Patras de Campaigno E, Ruetera M, Baricault B, Bourrel R, Lapeyre-Mestre M, Sommet A. Outpatient consumption of antibiotics with a bacterial resistance risk in 2014 in France. Therapie. 2017 ;72:593-604.

Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. Hydroxychloroquine-induced hearing loss : First case of positive rechallenge and analysis of the French pharmacovigilance database. Rev Med Interne. 2017 ;38:340-343.

Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017 ;84:213-215.

Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, Bagheri H, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits. Therapie. 2016 ;72:351-355.

Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017 ;86:168-175.

Falkowski S, Woillard JB, Postil D, Tubiana-Mathieu N, Terrebonne E, Pariente A, Smith D, Guimbaud R, Thalamas C, Rouguieg-Malki K, Marquet P, Picard N. Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer : a case control study. BMC Cancer. 2017 ;17:901.

Formoso G, Font-Pous M, Ludwig WD, Phizackerley D, Bijl D, Erviti D, Pospisilova B, Montastruc JL. Drug information by public health and regulatory institutions : results of an 8-coutry survey in Europe. Health Policy. 2017:121 ;257-264.

Fuzier R, Puel F, Izard P, Sommet A, Pierre S. Prospective cohort study assessing chronic pain in patients following minor surgery for breast cancer. J Anesth. 2017 ;31:246-254.

Gallini A, Coley N, Andrieu S, Lapeyre-Mestre M, Gardette V. Effect of dementia on receipt of influenza vaccine : a cohort study in French older adults using administrative data : 2007-2012. Fundam Clin Pharmacol. 2017 ;31:471-80.

Gautier Y, Montastruc F. Pharmacovigilance, une consultation pour les pathologies médicamenteuses. Le Moniteur des Pharm. 2017 ;3158:19.

Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc JL. Duloxetine and gingival bleeding : a case-report and reviews of the French and World PharmacoVigilance Databases and literature. Eur J Clin Pharmacol. 2017 ;73:1197-98.

Humbert X, Dolladille C, Sassier M, Valnet-Rabier MB, Vial T, Guitton E, Page A, Sole E, Auriche P, Coquerel A, Alexandre J, Fedrizzi S. Fibrates and risk of venous thromboembolism : Case/no-case study in French pharmacovigilance database. Therapie. 2017 ;72:677-682.

Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. Can drugs induce or aggravate Sleep Apneas ? A case non case Study in Vigibase®, the WHO Pharmacovigilance Database. Fundam Clin Pharmacol. 2017 ;31:359-366.

Mezaache S, Derumeaux H, Ferraro P, Capdepon P, Steinbach JC, Abballe X, Palas D, Saichi N, Desboeuf K, Lapeyre-Mestre M, Sailler L, Moulis G. Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. Eur J Haematol. 2017 ;99:344-349.

Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, Bagheri H. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes ? A population-based cohort study in France. Eur J Clin Pharmacol. 2017.73 ;471-77.

Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, Montastruc JL, Montastruc F. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy : a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017 ;59:329-334.

Montastruc JL, Durrieu G, Lacroix I, Lapeyre-Mestre M, Damase-Michel C, Bagheri H, Sommet A. Quelle Pharmacovigilance pour les vaccins ?. Bull. Acad. Natle. Mèd. Publi 2016. 2017 ;200:35.

Montastruc F, Sommet A, Montastruc JL. Concomitant medications and obstructive sleep apnoea. Br J Clin Pharmacol. 2017 ;83:2315-2316.

Montastruc F, Moulis F, Araujo M, Chebanne L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with parkinson’s disease. Eur Jour Clin Phar. 2017 ;73:99-103.

Montastruc F, Benevent J, Rousseau V, Chebane L, Bondon‐Guitton E, Durrieu D, Montastruc JL, Sommet A. Statins and diabetes : Is there any difference between the different statins ?. Pharmacoepidemiol Drug Saf. 2017 ;26:1296-1297.

Moulis F, Rousseau V, Abadie D, Masmoudi K, Micallef J, Vigier C, Pierre S, Dautriche A, Montastruc F, Montastruc JL. Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015.Therapie. 2017 ;72:615-624.

Moulis G, Lapeyre-Mestre M, Adoue D, Sailler L. Epidemiology and pharmacoepidemiology of immune thrombocytopenia. French. Rev Med Interne. 2017 ;38:444-449.

Moulis G, Lapeyre-Mestre M, Palmaro A, Sailler L. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults : risk factors and vaccination effect. J Thromb Haemost. 2017 ;15:1-7.

Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D ; CARMEN investigators group.. Newly diagnosed immune thrombocytopenia adults : clinical epidemiology, exposure to treatments and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017 ;92:493-500.

Moulis G, Guénin S, Limal N, Michel M, Bierling P, Godeau B, Mahévas M.  Seasonal variations of incident primary immune thrombocytopenia in adults : An ecological study. Eur J Intern Med. 2017 ;37:e26-e28.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK ; International DILI consortium (iDILIC), Drug-induced liver injury network (DILIN) investigators and International Serious Adverse Events Consortium (iSAEC). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 2017 ;152:1078-1089.

Nguyen TTH, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F. An original pharmacoepidemiologic - pharmacodynamic method : application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017 ;83:612-622.

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017 ;234:3075-81.

Palmaro A, Boucherie Q, Dupouy J, Micallef J, Lapeyre-Mestre M. Immeasurable time bias due to hospitalization in medico-administrative databases : which impact for pharmacoepidemiological studies ?. Pharmacoepidemiol Drug Saf. 2017 ;26:544-553.

Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M. Real-life practices for preventing venous thromboembolism in multiple myeloma patients : a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf. 2017 ;26:578-586.

Palmaro A, Gauthier M, Despas F, Lapeyre-Mestre M.  Identifying cancer drug regimens in French health insurance database : An application in multiple myeloma patients. Pharmacoepidemiol Drug Saf. 2017 ;26:1492-1499.

Palmaro A, Gauthier M, Conte C, Grosclaude P, Despas F, Lapeyre-Mestre M.  Identifying multiple myeloma patients using data from the French health insurance databases : Validation using a cancer registry. Medicine (Baltimore). 2017 ;96:e6189.

Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-Induced Dental Caries : A Disproportionality Analysis Using Data from VigiBase. Drug Saf. 2017 ;40:1249-1258.

Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, Despas F. Identification of Cellular targets involved in cardiac failure caused by PKI in oncology : an approach combining Pharmacovigilance and Pharmacodynamics. Br J Clin Pharmacol. 2017 ;83:1544-1555.

Récoché I, Lebaudy C, Cool C, Sourdet S, Piau A, Lapeyre-Mestre M, Vellas B, Cestac P. Potentially inappropriate prescribing in a population of frail elderly people. Int J Clin Pharm. 2017 ;39:113-119.

Severino-Freire M, Lamant L, Bagheri H, Mazereeuw-Hautier J, Paul C. Drug eruption with clomifene citrate in a bodybuilder. Ann Dermatol Venereol. 2017 ;144:636-637.

Sommet A, Lapeyre-Mestre M. Drug Use and Mortality in Parkinson Disease. J Am Med Dir Assoc. 2017 ;18:989.

Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A. Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. J Am Med Dir Assoc. 2017 ;18:791-796.

Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P. Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study. Rev Med Interne. 2017 ;38:167-175.


Bouvenot G, Sassard J, Montastruc JL. For an optimal use of fixed drug combinations. Therapie. 2017 ;72:665-668.

Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ. Movement Disorders Society MSA Study Group. Critical appraisal of clinical trials in multiple system atrophy : Toward better quality. Mov Disord. 2017 ;32:1356-1364.

Chevassus H, Duchesne C, Sailly A, Vigouroux C, Foulon C, Kubiak C, Binquet C, Felin AL, Chaud P, Thalamas C, Cornu C ; QUALI-CIC. Good professional practices of French CICs - version n° 2. Therapie. 2017 ;72:525-538.

Dupouy J, Ory-Magne F, Brefel-Courbon C. Other care in Parkinson’s disease : Psychological, rehabilitation, therapeutic education and new technologies. Presse Med. 2017 ;46:225-232.

Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C ; PARKMIP group. Cognitive complaint in early Parkinson’s disease : A pilot study. Acta Neurol Scand. 2018 ;137:59-66.

Gueyffier F, Piedbois P, Bergmann JF, the participants of Giens XXXII Round Table No. 2, Avouac B,Borel T, Boussageon R, Brun-Strang C, Braunstein D, Cazeneuve B, Diviné M, Dufour P, Girerd N, Laigle V, Le Jeunne C, Liard F, Marsot A, Montastruc JL, Trinh-Duc A, Vicaut E. How to measure the net benefit of treatment ?. Thérapie. 2017 ;72:51-61.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P ; BIPARK-2 Study Investigators.. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations : A Randomized Clinical Trial. JAMA Neurol. 2017 ;74:197-206.

Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA. Expert Rev Neurother. 2017 ;17:649-659.

Montastruc JL. Comment exprimer les résultats des études cliniques. Actual Pharmacol Clin. 2017 ;109 ;12.

Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O ; of the COPARK Study Group. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life : the COPARK survey. Eur J Neurol. 2017 ;24:1532-1538.

Ravoire S, Lang M, Perrin E ; participants of Giens XXXII Round Table No. 6. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapie. 2017 ;72:135-143.

Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S. Parkinson’s patients can rely on perspective cues to perceive 3D space. Brain Res. 2017 ;1663:161-165.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ ; Preladenant Early Parkinson Disease Study Group. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017 ;88:2198-2206.

Thibault L, Rascol O, Corvol JC, Ferreira J, Defebvre L, Deplanque D, Bordet R, Moreau C, Devos D. New perspectives on study designs for evaluating neuroprotection in Parkinson’s disease. Mov Disord. 2017 ;32:1365-1370.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk Lymphoma. 2017 ;58:1880-1886.


Beau AB, Tauber M, Chollet C, Hurault-Delarue C, Bouilhac C, Montastruc JL, Lacroix I, Damase-Michel C. A contemporary description of French newborns’ growth using the Efemeris cohort. Arch Pediatr. 2017 ;24:424-431.

Beau AB, Didier A, Hurault-Delarue C, Montastruc JL, Lacroix I, Damase-Michel C. Prescription of asthma medications before and during pregnancy in France : An observational drug study using the EFEMERIS database. J Asthma. 2017 ;54:258-264.

Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017 ;16:1181-90.

Benevent J, Bouton J, Damase-Michel C. Effets indésirables gynécologiques des anti-facteur de nécrose tumorale ; Gynaecological side effects of TNF-inhibitors. Rep Gyn End. 2017 ;19:146-52.

Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations : population based European register study. BMJ. 2017 ;356:j629.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure : example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 ;26:561-569

Salgues M, Damase-Michel C, Montastruc JL, Lacroix I. Women’s knowledge of folic acid. Therapie. 2017 ;72:339-343.


Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre M. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice : A 7-Year Cohort Study. Ann Fam Med. 2017 ;15:355-358.

Dupouy J, Lapeyre-Mestre M, Oustric S. Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder : a commentary. Pain. 2017 ;158:6-7.

Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, Jouanjus É, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J ; le Réseau français d’addictovigilance. Surveillance system on drug abuse : Interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017 ;72:491-501.

Jouanjus E, Mallaret M, Micallef J, Ponté C, Roussin A, Lapeyre-Mestre M. Comment on : "Social Media Mining for Toxicovigilance : Automatic Monitoring of Prescription Medication Abuse from Twitter". Drug Saf. 2017 ;40:183-185.

Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products ? A Systematic Review. Curr Atheroscler Rep. 2017 ;19:26.

Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav. 2017 ;70:355-363.

Ponté C, Lapeyre-Mestre M. Psychoactive effects of ’legal high’ : About lysergic acid amide (LSA). Therapie. 2017 ;72:605-608.

Ponté C, Pi C, Palmaro A, Jouanjus E, Lapeyre-Mestre M ; French Addictovigilance Network. Early Signal of Diverted Use of Tropicamide Eye Drops in France. Br J Clin Pharmacol. 2017 ;83:1791-1800.

Rolland B, Auffret M, Labreuche J, Lapeyre-Mestre M, Dib M, Kemkem A, Grit I, Drelon M, Duhamel A, Cabe N, Vabret F, Guillin O, Baguet A, Masquelier C, Dervaux A, Deheul S, Bordet R, Carton L, Cottencin O, Jardri R, Gautier S. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder : the BACLOPHONE cohort study protocol. Expert Opin Drug Saf. 2017 ;16:125-132.


Onfroy L, Galandrin S, Pontier SM, Seguelas MH, N’Guyen D, Sénard JM, Galés C. G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning. Sci Rep. 2017 ;7:7885.

Smolyakov G, Cauquil M, Severac C, Lachaize V, Guilbeau-Frugier C, Sénard JM, Galés C, Dague E. Biophysical properties of cardiomyocyte surface explored by multiparametric AFM. J Struct Biol. 2017 ;198:28-37.


Besnier F, Labrunée M, Pathak A, Pavy-Le Traon A, Galès C, Sénard JM, Guiraud T. Exercise training-induced modification in autonomic nervous system : An update for cardiac patients. Ann Phys Rehabil Med. 2017 ;60:27-35.

Besnier F, Sénard JM, Grémeaux V, Riédel M, Garrigues D, Guiraud T, Labrunée M. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication : study protocol for a randomised controlled trial : the TENS-PAD study. Trials. 2017 ;18:373.

Boudou N, Despas F, Van Rothem J, Lairez O, Elbaz M, Vaccaro A, Lebrin M, Pathak A, Carrié D. Direct evidence of sympathetic hyperactivity in patients with vasospastic angina. Am J Cardiovasc Dis. 2017 ;7:83-88.

Guiraud T, Labrunée M, Besnier F, Sénard JM, Pillard F, Rivière D, Richard L, Laroche D, Sanguignol F, Pathak A, Gayda M, Gremeaux V. Whole-body strength training with Huber Motion Lab and traditional strength training in cardiac rehabilitation : A randomized controlled study. Ann Phys Rehabil Med. 2017 ;60:20-26.